Chronic Pain and Opioid Use in US Soldiers After Combat Deployment
Chronic pain affects a quarter of people seeking primary health care.
1,2 Opioid medications are prescribed for chronic pain, but recently, rates of opioid use and misuse have ballooned, leading to significant numbers of overdose-related hospitalizations and deaths. 3 The prevalence of chronic pain and opioid use assoc iated w ith deployment is not well known, despite large numbers of wounded service members. To our knowledge, this is the first study to assess chronic pain prevalence and opioid use in a nontreatment-seeking, active duty infantry population following deployment.
Methods | Institutional review board approval for the study was given by Walter Reed Army Institute of Research. Confidential surveys were collected in 2011 from 1 infantry brigade 3 months after return from Afghanistan under a protocol approved by the Walter Reed Army Institute of Research. 4 Group recruitment briefings were attended by 80.3% of soldiers (3076 of 3832); 93.5% consented to participate (2876 of 3076). The final sample included 2597 soldiers who had been deployed to Afghanistan or Iraq. Participants provided written informed consent. Chronic pain was defined by soldiers reporting pain duration of at least 3 months (Table 1) . 5 Past-month pain frequency and severity (range, 0-10; none [0], mild [1] [2] [3] [4] , moderate [5] [6] , and severe [7] [8] [9] [10] ) 6 were also assessed (Table 1) .
Opioids and other pain medications were assessed by pastmonth frequency of use (never, few or several days, more than half the days, nearly every day) (Table 1) . Standardized scales assessed injuries during combat, combat intensity, posttraumatic stress disorder (PTSD), major depressive disorder (MDD) and alcohol misuse. 4 Multiple logistic regressions examined correlates of chronic pain and opioid use.
Results | The 2597 participants were predominantly male (93.1%), 18 to 24 years old (41.3%), high school educated (48.2%), married (54.9%), and junior enlisted rank (56.1%). Nearly half (45.4%) reported injuries during combat. The prevalences of PTSD, MDD, and alcohol misuse screening were 9.1%, 5.8%, and 16.4%, respectively. Past-month opioid use was reported by 15.1% of soldiers (Table 1) ; among these, 5.6% reported no past-month pain, and 38.5%, 37.7%, and 18.2% reported mild, moderate, and severe pain, respectively. Most using opioids (62.6%) reported few or several days' use. Chronic pain was reported by 44.0%. Of these, 48.3% reported duration 1 year or longer, 55.6% reported nearly daily or constant frequency, and 51.2% reported severity of moderate to severe; 23.2% reported past-month opioid use, and 57.9% of those reported few or several days use (Table 1) .
Chronic pain was significantly associated with age 30 years or older, being married or having been married previously, injury during combat, combat intensity, PTSD, and MDD ( Table 2) . Opioid use was associated with sex, age 25 years or older, being married, rank, injury during combat, chronic pain, and pain severity (Table 2) . 
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Discussion | The prevalence of chronic pain (44.0%) and opioid use (15.1%) in this non-treatment-seeking infantry sample were higher than estimates in the general civilian population of 26.0% and 4.0%, respectively. 2 These results are notable because this is an operational unit of young soldiers surveyed at their workplace and are likely, in part, related to deployment effects (including injuries, combat exposure, and mental health conditions). These findings suggest a large unmet need for assessment, management, and treatment of chronic pain and related opioid use and misuse in military personnel after combat deployments. Notably, 44.1% of soldiers reporting opioid use reported no or mild past-month pain, including 5.6% with no pain. This might imply that opioids are working to mitigate pain, but it is also possible that soldiers are receiving or using these medications unnecessarily. This is cause for concern because opioids should be prescribed generally for moderate to severe pain 1,3 and have high abuse and overdose potential.
1-3 Prescription practices should be examined to ensure that opioid use is consistent with standards of care and practice guidelines and nonopioid alternatives are considered whenever possible. 1, 3 The benefits of opioids for treating pain, particularly in those with combat-related injuries, must be balanced by careful assessment of risks, including the potential for misuse. Institute of Medicine (IOM) called for a comprehensive pain management plan with specific goals, actions, and timeframes. They recommended that the goal should be nothing short of a "cultural transformation" in how we manage pain, noting that over 100 million people experience chronic pain at an annual cost of over $600 billion. Notably, they urged a plan that tailored pain management to each person and that more and better strategies for "self-management of pain be promoted." 4(p3) A year before this IOM report, in response to the growing prevalence of pain from a decade of continuous combat, the Department of Defense (DoD) took up this challenge. The Army, joined by the other Services, the Veterans Administration, and leading civilian pain experts, established a Pain Management Task Force. The DoD developed a comprehensive Pain Management Campaign with 109 specific action items with an aim to create an integrated approach to pain that is "…holistic, multidisciplinary, and multimodal in its approach, utilizes state of the art/science modalities and technologies, and provides optimal quality of life for soldiers and other patients with acute and chronic pain." 5 This campaign has continued unabated within the DoD. For example, the Army has moved forward with a variety of initiatives to improve treatment effectiveness and risk reduction related to polypharmacy, among them those aimed at reducing adverse outcomes due to prescription abuse. These include informed consent for polypharmacy, a sole health care provider program for frequent prescription drug users, limiting the authorized use of a prescription to 6 months following the fill date, adding hydrocodone and hydromorphone to the panel in random urine drug testing, and polypharmacy education and training. Drug take-back programs at hospital and clinic pharmacies have begun improving medical oversight and improving health record documentation.
Among the first tasks needed to fully implement the IOM and DoD Pain Management Campaign recommendations was to examine the evidence basis for "self-management" strategies. The DoD commissioned Samueli Institute, a nonprofit research organization, to conduct a comprehensive set of systematic reviews on self-care and integrative approaches for pain. An expert committee called the Active Self-Care Therapies for Pain (PACT) Working Group was convened to make recommendations based on these reviews. The PACT included the director of the Defense and Veterans Center for Integrated Pain Management and 7 other subject matter experts. That PACT evidence review and recommendations were recently published in Pain Medicine. 6 From the available literature, the committee recommended that several self-care modalities be adopted as effective for alleviating chronic pain, including yoga, t'ai chi, and music therapy. More than 10 other selfmanagement approaches had insufficient evidence to recommend them, primarily because of a lack of studies and poor research design. It was clear that much more investment was needed for understanding and delivering these modalities. But is that likely to happen? Achieving the IOM and DoD recommendations will require overcoming major obstacles, especially where we are investing our money for pain management. Despite the public costs of inadequately managed pain listed by IOM, the National Institutes of Health currently spends only 1% of its $30 billion budget for pain research. Compare this with private sector spending on pharmaceuticals, estimated at $48.5 billion for research and development and $57.5 billion for drug promotion. 4 If only 1% of that is for pain, this amount dwarfs what goes into self-management. Although opioid medications are effective in treating acute pain, their use in chronic pain management is not well supported by the available evidence 7 and is associated with clinically significant adverse events. In the Research Letter by Toblin et al 2 in this issue, 44.1% of soldiers reporting opioid use had no or mild past-month pain, including 5.6% with no pain. As the authors point out, 2 given the high abuse potential for opioids, this is also a cause for concern. Unless the "cultural transformation" called for by the IOM begins in earnest, our nation faces additional crises in the future. Many service members and veterans with pain also have comorbid conditions, such as posttraumatic stress syndrome or traumatic brain injury. Many of them are at risk for a lifetime progression of increasing disability unless the quality, variety, and accessibility of evidenced-based "self-management" skills are improved. Without more effective and less costly approaches to pain management, the estimated costs of care and disability to the country will approach $5 trillion. 8 The loss of human potential is inestimable. This staggering cost will become the greatest threat to national defense as the nation is crushed under debt. Thus, for reasons of current and future national strength, and most important, the suffering of our service members and veterans, we must transform ourselves in the way we manage pain. We can and must do better.
Effects of Ranolazine on Quality of Life Among Patients With Diabetes Mellitus and Stable Angina
In the Type 2 Diabetes Evaluation of Ranolazine in Subjects with Chronic Stable Angina (TERISA) trial, ranolazine reduced the frequency of angina episodes and use of sublingual nitroglycerin in patients with type 2 diabetes mellitus (T2DM) and stable angina, as assessed by a daily diary. 1 Using data from the same trial, we evaluated the effect of ranolazine on a broader range of patients' health status and quality of life.
Methods | TERISA was approved by the national regulatory authority in each participating country and the institutional review board or local ethics committee for each site, and all participating patients provided written informed consent. TERISA was a randomized, double-blind, placebo-controlled trial in 104 sites in 14 countries in which patients with chronic stable angina receiving 1 to 2 antianginal medications and T2DM were randomized to placebo or ranolazine (Gilead Sciences; dosage goal, 1000 mg twice daily) for 8 weeks.
1 Health status was assessed at baseline and at 8 weeks with the Seattle Angina Questionnaire (SAQ), 2 Rose Dyspnea Scale, 3 and the Medical
Outcomes Short Form-36 (SF-36) component scores. 4 A 10-point increase in SAQ angina frequency represents a clinically important intraindividual change. 2 Linguistically valid, country-specific instruments were used. Scores were compared using analysis of covariance, adjusted for baseline health status and prespecified stratification covariates. 1 We tested interactions between treatment and baseline angina; number of antianginals; geography (Russia, Ukraine, and Belarus vs other [as prespecified in the TERISA analytic plan]), age, and sex.
Results | Overall, 917 patients were randomized: mean age of 64 years, 61% men, 99% white, and mean hemoglobin A 1c level of 7.3%. Both treatment groups had high symptom burden at baseline and experienced improvements in all health status measures at follow-up (Table) . Compared with placebo, ranolazine significantly improved SAQ angina frequency, treatment satisfaction, and SF-36 physical component summary scale scores. These effects did not differ for all measures across each of the prespecified subgroups (geography, baseline angina episodes, number of antianginals, sex, and age [P > .05 for all interactions]), except the SF-36 mental component, which improved more with ranolazine in other countries (mean effect, 1.8; 95% CI, 0.01 to 3.5) than in Russia, Ukraine, and Belarus (mean effect, −0.9; 95% CI, −2.0 to 0.2 [P value for interaction, .009]). A greater percentage of patients treated with ranolazine vs placebo had at least a 10-point improvement in SAQ angina frequency scores (67% vs 58% [P = .004]; Figure) , suggesting that 11 patients need to be treated with ranolazine for 1 to experience a clinically significant improvement in angina. The number needed to treat was lower among patients taking more 
